Transgenomic, Inc. And University of Melbourne Collaborate To Further Validate Ability Of Multiplexed ICE COLD-PCRTM To Enable Personalized Cancer Treatment

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a research agreement with the University of Melbourne to conduct additional clinical validation studies of its Multiplexed ICE COLD-PCRTM (MX-ICP) technology. MX-ICP is a high sensitivity DNA amplification technology that allows the simultaneous detection of multiple mutations in multiple genes from tumor samples or any liquid sample, such as blood or urine.

Help employers find you! Check out all the jobs and post your resume.